Anti-inflammatory drug approved for use after cataract surgery

Article

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

Yellox, owned by CROMA, is to be administered twice daily as an ocular NSAID in adult patients after undergoing cataract surgery. Otherwise known as, Yellox (bromfenac sodium) targets the COX-2 enzyme- one of the prime causes of prostaglandin production and ocular inflammation. The solution penetrates through the cornea and ocular tissues to treat ocular inflammation.

CROMA will collaborate with Bausch+Lomb to promote the ophthalmic solution in Austria, France, Spain, Poland and Romania. Bausch+Lomb will manage promotions in the remaining EU countries.

Chief Medical Officer of Bausch+Lomb, Dr Cal Roberts, said: “Yellox is very promising for cataract surgery patients. The drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.”

Recent Videos
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
© 2024 MJH Life Sciences

All rights reserved.